A phase II randomised double-blind, double-dummy, placebo-controlled study was conducted in recent-onset individuals with T1D, where they received either anti-IL21, anti-IL-21 with liraglutide, liraglutide alone or placebo (77 individuals per treatment arm) [109]. Here, IL21 is linked to type 1 diabetes mellitus.